This extended endocrine/intracrine environment is demonstrated by the presence of an expanded panel of nuclear receptors (AR, GR, and ERβ1), as well as the multitude of steroid metabolising enzymes that can interconvert steroid already present in the tumour or make additional pools of circulating steroid available to the tumour. The gene discussed is AR; the disease is neoplasm.